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Mice with chronic granulomatous disease (X-CGD mice) gen-
erated by mutating the X-linked gene for a subunit of NADPH
oxidase have been analyzed for their ability to respond to in-
travenous injection of purified cobra venom factor (CVF).
This agent in wild-type mice produces a neutrophil-depen-
dent and catalase-sensitive form of lung injury. Lung injury
was evaluated by measuring the accumulation of extravas-
cular albumin. Quite unexpectedly, the lungs of X-CGD
mice showed no difference in the increased accumulation of
extravascular albumin after injection of CVF when com-
pared to wild-type mice. In both X-CGD and wild-type mice,
full development of injury required neutrophils. While cata-
lase was highly protective in wild-type mice, its protective
effects were completely lost in the X-CGD mice. Further-












-arginine, was protective in X-CGD mice but not in wild-
type mice. Allopurinol was protective in both types of mice.
Both the basal and the CVF-inducible lung mRNA for in-




 was similar in
X-CGD and wild-type mice. These data indicate that oxy-
gen radical production and lung injury in response to injec-
tion of CVF occurs through alternative pathways in mice
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of rare inherited disorders characterized by defects in a phago-
cyte-specific NADPH-oxidase complex that forms the super-
oxide radical during the respiratory burst and hydrogen perox-
ide (1). Mice with chronic granulomatous disease (X-CGD
mice) have been generated by mutating the X-linked gene for
the 91-kD subunit of NADPH oxidase (2). Neutrophils from






) formation by NADPH oxi-









, two important causes of in-





 pneumonia after instillation
of spores of this opportunistic pathogen into the respiratory
tract, which is associated with a high mortality compared to
wild-type mice (1, 2).
Intravenous infusion of cobra venom factor (CVF) into rats
or mice induces sequestration of neutrophils within the pulmo-
nary capillaries and an increase in vascular permeability (3, 4).
This acute lung injury requires sudden, massive activation of
complement, based on studies using soluble complement re-
ceptor 1 (5). The injury occurs within 30 min of infusion and is
self-limited and reversible. Both platelets and neutrophils are
also required, as demonstrated by depletion studies (3, 4). Fur-
thermore, neutrophil adhesion to endothelial cells appears to
be a key step in this injury, as demonstrated by studies in rats
using inhibitors which depress the function of adhesion mole-
cules (6–10). This injury also requires the production of oxy-




















































 may be important in this
injury, as demonstrated by the protective effect of iron chela-
tors and hydroxyl radical scavengers (3, 4, 11).
This study tested the hypothesis that X-CGD mice are re-
sistant to lung injury induced by CVF. The role of neutrophils
and the contribution of oxidants was also evaluated. Because
the initial studies showed that alternative pathways of oxygen-
derived radical production were used in the X-CGD mice,
studies investigating the production of murine inducible nitric











Mice with chronic granulomatous disease (X-CGD mice)
were generated by mutating the X-linked gene for the 91-kD subunit
of NADPH oxidase (2). These animals are completely deficient in
NADPH oxidase activity (2). Control animals were wild-type litter-
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 CGD, chronic granulomatous dis-
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Lung injury induced by CVF was evaluated by













X-CGD mice and five wild-type mice were studied in each group. The
mice were anesthetized by intramuscular injection of ketamine hy-
drochloride (Fort Dodge Laboratories, Inc., Fort Dodge, IA; 10 mg/





I-albumin (IHSAI 125; Mallinckrodt Medical, Inc., St.




Ci/mouse) was injected intravenously. 15 min
later, CVF (2.0 U/mouse) was injected intravenously. At 28 min after













jected intravenously to measure intravascular pulmonary blood vol-
ume. At 30 min, the mice were given an overdose of halothane. A
blood sample was collected from the inferior vena cava. The chest
was opened, and the base of the heart was rapidly tied off to prevent
blood loss from the lungs. The thoracic organs were removed, and the
lungs were fixed using intratracheal instillation of 6.0% glutaralde-
hyde in phosphate buffer. After 1 h, the lungs were separated from
the heart and mediastinal tissues. The lungs, reference blood sample,
and plasma sample were placed in scintillation vials and counted in a
gamma counter (Packard Instrument Co., Meriden, CT) linked to an
IBM computer for separation of multiple isotopes and correction for








Depletion of neutrophils. 
 
Wild-type and X-CGD mice were de-
pleted of neutrophils by intraperitoneal injection of cyclophospha-
mide (C 7397; Sigma Chemical Co., St. Louis, MO; 200 mg/kg dis-
solved in 0.4 ml saline/mouse). This procedure was repeated daily for





; Hoffmann-LaRoche Inc., Nutley, NJ; 75 mg/kg i.m.)
twice a day for 4 d to prevent infections. Circulating leukocyte and
neutrophil counts were evaluated in blood samples obtained from the
retro-orbital plexus using hemacytometer counts and Wright-stained
smears.
Lung injury was induced by intravenous injection of CVF in neu-
trophil-depleted wild-type and X-CGD mice, and the injury was eval-
uated as described above. Paraffin-embedded sections of lung tissue
were obtained to evaluate the presence of inflammatory foci as a
complication of neutropenia.
 
Inhibition of oxidant production. 
 
Catalase (C-40; Sigma Chemi-





















-arginine (L-NMA) (M 7033; Sigma Chemical Co., dissolved in saline
[10 mmol/l], 1.0 ml/mouse) was injected intraperitoneally to inhibit
nitric oxide synthase (NOS [14]). Allopurinol (A8003; Sigma Chemi-
















l saline/mouse) was injected intra-









I-albumin 15 min before the CVF injec-
tion. CVF-induced lung injury was evaluated as described above.
 





, and ICAM-1 mRNAs in lung tissue. 
 
Lungs from uninjured and








 3 in each group) were
frozen in liquid nitrogen. The tissue was pulverized in RNAzol (Tel-
Test, Inc., Friendswood, TX) and the total RNA was extracted fol-













51( ) / Cr-RBC/g blood51( ) 1 hematocrit2( )3
 
lowing the manufacturer’s instructions. Total RNA was run on aga-
rose/formaldehyde gels and transferred to nylon membranes. North-
ern blots were prepared as previously described after electrophoresis
of total RNA on an agarose/formaldehyde gel and transfer to Magna-
charge nylon membranes (Micron Separations, Westboro, MA [16]).
Conditions for hybridization and stripping were as suggested by the
manufacturer. Random-primed radiolabeled cDNA probes were gen-
erated using the Prime-a-Gene kit (Promega Corp., Madison, WI),
according to the manufacturer’s instructions. The murine iNOS
cDNA was kindly provided by Drs. Qiao-wen Xie and Carl Nathan





 cDNA by Dr. Patrick Gray (Genentech, Inc., South San Francisco,
CA), and the murine ICAM-1 cDNA from the American Type Cul-
ture Collection (#63111; Rockville, MD). To correct for differences in













the mean. Data were compared using analyses of variance (17). When
overall differences were identified, multiple contrasts with a Bonfe-
ronni adjustment were used to identify which groups were signifi-












Requirement for NADPH oxidase in CVF-induced lung injury.
 
The lungs of uninjured X-CGD mice that did not receive CVF
had similar values of EVA as those in wild-type mice (Fig. 1).
Intravenous injection of CVF caused a significant increase in
the accumulation of EVA in both wild-type mice and X-CGD
mice to values nearly double that found in uninjured mice. Un-
expectedly, the increase in EVA was similar in both X-CGD
and wild-type mice.
 
Effect of neutrophil depletion. 
 
Daily intraperitoneal instil-
lation of cyclophosphamide for 4 d resulted in virtually nonde-


























/ml in X-CGD mice). Histological evalua-
tion of lungs from either type of mouse showed no evidence of
infection or inflammation. In wild-type mice, the accumulation
of EVA was inhibited by 71% in neutropenic animals com-
pared to controls. Similarly, the increase in EVA was reduced
by 60% in the neutropenic X-CGD mice compared to X-CGD
mice with normal circulating numbers of neutrophils (Fig. 1).
These data indicate that neutrophils were required for full ex-
pression of CVF-induced injury in both X-CGD and wild-type
mice.
 
Effect of inhibitors of oxidant production on lung injury.
 
When mice were treated with catalase before intravenous infu-
sion of CVF, there was, as expected based on previous studies
(3), no increase in the accumulation of EVA in wild-type mice,
indicating that treatment with catalase was completely protec-
tive (Fig. 1). In striking contrast, no protective effects of cata-









 was no longer required for development of lung injury.
Both X-CGD and wild-type mice were also treated with





operative. While treatment with L-NMA was not protective in
the wild-type mice, this treatment in X-CGD mice completely
prevented the increase in the accumulation of EVA after infu-





pathway was engaged in X-CGD mice but not in wild-type
mice.
Because previous studies have shown that the xanthine oxi-






lopurinol, contributes to lung injury in rats (19), wild-type and
X-CGD mice were treated with allopurinol before injection of
CVF. Allopurinol significantly prevented the accumulation of

















l EVA without allopurinol) and in

















l EVA without allopurinol), suggesting that prod-
ucts of xanthine oxidase may be contributing to the outcome
of the injury.
 
Expression of iNOS, IL-1, and ICAM-1 mRNAs in lung tis-
sue. 
 
There was no difference in the basal expression of iNOS
mRNA in X-CGD mice compared to wild-type mice, and no
changes in the iNOS mRNA level were detected in either
X-CGD or wild-type mice 30 min after injection of CVF (Fig. 2).





uninjured lungs of X-CGD and wild-type mice. CVF induced a














Abundant quantities of ICAM-1 mRNA were observed in un-
injured lungs that were similar in X-CGD and wild-type mice,




In rats and mice, the development of lung injury after intravas-
cular injection of CVF is neutrophil and platelet dependent
and sensitive to protective effects of catalase and superoxide
dismutase (SOD) (3–5, 11). Surprisingly, X-CGD mice were
not resistant to CVF-induced injury, and their lungs developed
an injury similar to those of wild-type mice in response to
CVF. While neutrophils remained vital to the induction of
lung injury in the X-CGD mice, catalase was no longer able to
cause protective effects. The ability of L-NMA to protect
against injury in X-CGD mice but not wild-type mice suggests
that X-CGD mice are using alternative pathways of oxidant




NO-generating pathway. The protec-
Figure 1. Edema formation in 
CVF-induced lung injury in wild-
type and X-CGD mice. CVF in-
duced a similar lung injury in both 
wild-type mice (filled bars) and 
X-CGD mice (open bars) com-
pared to mice that received saline. 
Neutrophils were required for 
lung injury in both wild-type mice 
and X-CGD mice. Catalase inhib-
ited the injury in wild-type mice, 
but not X-CGD mice. L-NMA in-
hibited injury only in X-CGD 
mice. n 5 5 mice in each group. 
*Significantly different from unin-
jured mice pretreated with saline, 
P , 0.01. §Significantly different 
from mice pretreated with saline 
before injection of CVF, P , 0.01.
Figure 2. Expression of iNOS, IL-1b, and ICAM-1 mRNA in lung 
tissue. Wild-type (WT) and X-CGD (CGD) mice received cobra 
venom factor (CVF1, lanes 7–12) or saline (CVF2, lanes 1–6) as de-
scribed in Methods. 10 mg of total RNA was electrophoresed per 
lane. After transfer to a nylon membrane, the blot was sequentially 
probed with radiolabeled cDNAs for iNOS, IL-1b, ICAM-1, and 
b-actin, as shown. Differences in expression were assessed by densi-
tometry, with b-actin expression used to correct for differences in 
loading. The expression of iNOS mRNA was similar in uninjured 
lungs of wild-type and X-CGD mice and did not change after injec-
tion of CVF. The expression of IL-1b mRNA was similar in unin-
jured lungs of X-CGD mice compared to wild-type mice and in-
creased similarly in both types of mice after injection of CVF. The 
expression of ICAM-1 mRNA was also similar in X-CGD and wild-
type mice and did not increase after CVF.
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tive effects of allopurinol both in wild-type mice and in
X-CGD mice suggest that xanthine oxidase in either neutro-
phils, endothelial cells, or both is at least partially responsible
for O2? generation when these cells are activated.
Our studies taken together with those of other investiga-
tors, suggest a pathway through which injury occurs in wild-
type mice (Fig. 3). C5a generation after injection of CVF
causes upregulation of adhesion molecules (including CD11b/
CD18 on neutrophils and P-selectin on endothelial cells [6–
10]), facilitating adhesive interactions between neutrophils and
endothelial cells (6–10). Neutrophils activated by C5a generate
O2? from the NADPH oxidase, which is rapidly converted into
H2O2 by superoxide dismutase. H2O2 is then released rapidly
in the vicinity of endothelial cells. The generation of O2? by ei-
ther activated neutrophils or endothelial cells itself contributes
to the full development of endothelial cell injury, as demon-
strated by the partial protective effects of superoxide dismu-
tase (3, 4). O2? may react with intracellular endothelial ferritin,
resulting in reduction of Fe31 to its transition state, Fe21. H2O2
provided by activated neutrophils would then react with Fe21
within endothelial cells to generate hydroxyl radical (HO?), re-
sulting in endothelial cell injury. This pathway has been dem-
onstrated in vitro to explain killing of rat pulmonary artery
endothelial cells by activated neutrophils or by H2O2, the cyto-
toxic outcome being diminished by preloading endothelial
cells with allopurinol, superoxide dismutase, or iron chelators
(20–22). CVF-induced lung injury in rats is prevented by these
same interventions (11).
In X-CGD mice, these studies suggest that alternative
pathways resulting in lung vascular injury do not require oxi-
dants generated by NADPH oxidase. O2? may be the product
of xanthine oxidase contained in endothelial cells. As reflected
by the protective effects of L-NMA in X-CGD mice, neutro-
phils may be using an alternative oxygen-generating pathway
involving nitric oxide synthase which generates ?NO. ?NO
would then gain entry into endothelial cells, where it would re-
act with endothelial O2? generated by xanthine oxidase to form
the peroxynitrite (ONOO2), a highly reactive radical species
(23–25). Under conditions of protonation, HONOO would
then undergo homolytic cleavage to form HO? in endothelial
cells in the absence of requirement for a transition metal such
as Fe21.
Why this alternative pathway is not used in wild-type mice
given catalase is not readily apparent. The inability to detect
differences in iNOS mRNA obtained from lungs of X-CGD
compared to wild-type mice may reflect the insensitivity of this
technique and the possibility that 30 min may be insufficient
time for transcriptional and translational expression of iNOS.
However, the basal levels of iNOS present in neutrophils may
be sufficient for production of ?NO and lung injury by CVF in
X-CGD mice. Il-1b is known to cause enhanced production of
?NO by pulmonary artery smooth muscle cells and by alveolar
macrophages and rat type II pneumocytes (26, 27). Although
no differences in the upregulation of IL-1b mRNA were ob-
served in X-CGD mice when compared to wild-type mice, the
large increase suggests that this pathway of ?NO upregulation
was available in X-CGD mice.
While an alternative pathway may exist in X-CGD mice for
the production of O2? after infusion of CVF, this pathway does
not provide a fully intact antimicrobial defense mechanism for
the lung in response to infecting agents. In particular, this
pathway is insufficient for containment of Aspergillus in
X-CGD mice (2). In addition, this ?NO-generating pathway
can not compensate in the killing of coagulase negative Sta-
phylococcus aureus, since this organism has increased viru-
lence in X-CGD mice and patients with CGD (1, 2, and un-
published data).
In summary, these studies show that mice deficient in
NADPH oxidase use alternative pathways to mediate CVF-
induced lung injury. The use of these pathways demonstrates
the redundancies in the mechanisms through which protective
and injurious oxidants are made. The production of ?NO by
human neutrophils is controversial (19, 28, 29), and whether
this particular pathway involving production of ?NO is impor-
Figure 3. Diagram describing pos-
tulated alternative pathways of ox-
ygen-derived radical production in 
X-CGD compared to wild-type 
mice. Please see text for details.
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tant in patients with CGD remains to be determined. How-
ever, the data presented in this manuscript provide evidence
that biological systems can use alternative pathways to com-
pensate for the loss of an important molecule.
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